Calaspargase pegol desensitization results
| Patient . | Immunophenotype/phase of therapy . | Age at diagnosis (y) . | Symptoms and formulation of initial ASP HSR . | Time from initial HSR to desensitization (d) . | Desensitization dose (n) . | Dose given, dose intended (units/m2) . | HSR during desensitization (Y/N) . | Completed infusion (Y/N) . | Desensitization reaction symptom . | Estimated to maintain SAA ≥0.1 IU/mL for at least 21 days (Y/N) . | SAA results (IU/mL) . | Estimated time ≥0.1 IU/mL (d) . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | B-cell/front-line therapy | 5.4 | Cough, nausea; CAL-PEG | 7 | 1 | 677, 2500 | Y | N | Cough | N | EOI: <0.06 | 0 |
| 2 | B-cell/front-line therapy | 3.5 | N/A, silent inactivation identified during induction to CAL-PEG | 167 from induction dose | 1 | 2459, 2500 | N | Y | N/A | N | EOI: 1.466 Day after: 1.244 5 days: <0.06 | 5 |
| 3 | B-cell/front-line therapy | 3.4 | Rash; CAL-PEG | 8 | 1 | 2500, 2500 | N | Y | N/A | N | EOI: 1.715 Day after: 1.177 6 days: 0.709 11 days: <0.06 | 10.2 |
| 4 | B-cell/front-line therapy | 14.6 | Chest tightness and difficulty breathing, nausea and vomiting requiring epinephrine and oxygen; pegaspargase | 17 | 1 | 1535, 2500 (dose capped at 3750 units) | N | Y | N/A | N | EOI: 0.612 Day after: 0.561 6 day: 0.498 34 days: <0.06 | 15.9 |
| 52 | 2 | 171.6, 2500 | Y | N | Cough, rash, and angioedema of his lips | N | EOI: <0.06 | 0 | ||||
| 5 | B-cell/front-line therapy | 3 | Facial rash and flushing on tips of ears, nausea; CAL-PEG | 21 | 1 | 0.89, 2500 | Y | N | Facial flushing | N | N/A | 0 |
| 6 | B-cell/front-line therapy | 3 | Cough, flushed cheeks, hives on cheeks, emesis; CAL-PEG | 72 | 1 | 2500, 2500 | N | Y | N/A | Y | EOI: 1.622 Day after: 1.329 6 day:1.462 | 21.6 |
| 7 | B-cell/relapsed | 10.9 | Rash; pegaspargase | ∼3 years, reaction at outside hospital. Exact date unknown | 1 | 2500, 2500 | N | Y | N/A | Y | EOI: 1.233 Day after: 1.295 2 day: 1.25 6 day: 0.884 13 day: 0.822 20 day: 0.6 | 44.5 |
| 2 | 1000, 1000 | N | Y | N/A | Y | EOI: 0.88 11 day: 0.326 23 day: 0.243 27 day: 0.075 | 28.6 | |||||
| 8 | B-cell/relapsed | 10 | Tachycardia, fever, urticaria, eyelid swelling; pegaspargase | 826 | 1 | 2500, 2500 | N | Y | N/A | N | EOI: 1.516 Day after: 1.53 2 day: 1.233 | 17.8 |
| 9 | B-cell/relapsed | 6.8 | Unknown, occurred at OSH to pegaspargase. Tolerated pegaspargase desensitization | Unknown, occurred at OSH but ∼1 year off therapy before relapse | 1 | 2500, 2500 | N | Y | N/A | Y | EOI: 1.219 Day after: 0.997 12 day: 1.462 | 23.5 |
| Patient . | Immunophenotype/phase of therapy . | Age at diagnosis (y) . | Symptoms and formulation of initial ASP HSR . | Time from initial HSR to desensitization (d) . | Desensitization dose (n) . | Dose given, dose intended (units/m2) . | HSR during desensitization (Y/N) . | Completed infusion (Y/N) . | Desensitization reaction symptom . | Estimated to maintain SAA ≥0.1 IU/mL for at least 21 days (Y/N) . | SAA results (IU/mL) . | Estimated time ≥0.1 IU/mL (d) . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | B-cell/front-line therapy | 5.4 | Cough, nausea; CAL-PEG | 7 | 1 | 677, 2500 | Y | N | Cough | N | EOI: <0.06 | 0 |
| 2 | B-cell/front-line therapy | 3.5 | N/A, silent inactivation identified during induction to CAL-PEG | 167 from induction dose | 1 | 2459, 2500 | N | Y | N/A | N | EOI: 1.466 Day after: 1.244 5 days: <0.06 | 5 |
| 3 | B-cell/front-line therapy | 3.4 | Rash; CAL-PEG | 8 | 1 | 2500, 2500 | N | Y | N/A | N | EOI: 1.715 Day after: 1.177 6 days: 0.709 11 days: <0.06 | 10.2 |
| 4 | B-cell/front-line therapy | 14.6 | Chest tightness and difficulty breathing, nausea and vomiting requiring epinephrine and oxygen; pegaspargase | 17 | 1 | 1535, 2500 (dose capped at 3750 units) | N | Y | N/A | N | EOI: 0.612 Day after: 0.561 6 day: 0.498 34 days: <0.06 | 15.9 |
| 52 | 2 | 171.6, 2500 | Y | N | Cough, rash, and angioedema of his lips | N | EOI: <0.06 | 0 | ||||
| 5 | B-cell/front-line therapy | 3 | Facial rash and flushing on tips of ears, nausea; CAL-PEG | 21 | 1 | 0.89, 2500 | Y | N | Facial flushing | N | N/A | 0 |
| 6 | B-cell/front-line therapy | 3 | Cough, flushed cheeks, hives on cheeks, emesis; CAL-PEG | 72 | 1 | 2500, 2500 | N | Y | N/A | Y | EOI: 1.622 Day after: 1.329 6 day:1.462 | 21.6 |
| 7 | B-cell/relapsed | 10.9 | Rash; pegaspargase | ∼3 years, reaction at outside hospital. Exact date unknown | 1 | 2500, 2500 | N | Y | N/A | Y | EOI: 1.233 Day after: 1.295 2 day: 1.25 6 day: 0.884 13 day: 0.822 20 day: 0.6 | 44.5 |
| 2 | 1000, 1000 | N | Y | N/A | Y | EOI: 0.88 11 day: 0.326 23 day: 0.243 27 day: 0.075 | 28.6 | |||||
| 8 | B-cell/relapsed | 10 | Tachycardia, fever, urticaria, eyelid swelling; pegaspargase | 826 | 1 | 2500, 2500 | N | Y | N/A | N | EOI: 1.516 Day after: 1.53 2 day: 1.233 | 17.8 |
| 9 | B-cell/relapsed | 6.8 | Unknown, occurred at OSH to pegaspargase. Tolerated pegaspargase desensitization | Unknown, occurred at OSH but ∼1 year off therapy before relapse | 1 | 2500, 2500 | N | Y | N/A | Y | EOI: 1.219 Day after: 0.997 12 day: 1.462 | 23.5 |
ASP, asparaginase; EOI, end of infusion; HSR, hypersensitivity reaction; N, no; N/A, not applicable; OSH, outside hospital; Y, yes.